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Omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are found naturally in
ﬁsh oil and are commonly thought to be anti-inﬂammatory nutrients, with protective effects in in-
ﬂammatory diseases including asthma and allergies. The mechanisms of these effects remain mostly
unknown but are of great interest for their potential therapeutic applications. Large numbers of
epidemiological and observational studies investigating the effect of ﬁsh intake or omega-3 fatty acid
supplementation during pregnancy, lactation, infancy, childhood, and adulthood on asthmatic and
allergic outcomes have been conducted. They mostly indicate protective effects and suggest a causal
relationship between decreased intake of ﬁsh oil in modernized diets and an increasing number of in-
dividuals with asthma or other allergic diseases. Specialized pro-resolving mediators (SPM: protectins,
resolvins, and maresins) are generated from omega-3 fatty acids such as EPA and DHA via several
enzymatic reactions. These mediators counter-regulate airway eosinophilic inﬂammation and promote
the resolution of inﬂammation in vivo. Several reports have indicated that the biosynthesis of SPM is
impaired, especially in severe asthma, which suggests that chronic inﬂammation in the lung might result
from a resolution defect. This article focuses on the beneﬁcial aspects of omega-3 fatty acids and offers
recent insights into their bioactive metabolites including resolvins and protectins.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosa-
pentaenoic acid (EPA), are polyunsaturated fatty acids found
mainly in ﬁsh oil. Epidemiological studies have shown that these
compounds play protective roles in cardiovascular diseases
such as myocardial or cerebral infarction, hypertension, andics, RIKEN Center for Inte-
i-ku, Yokohama, Kanagawa
ety of Allergology.
rgology. Production and hosting by Elshyperlipidemia.1 Also, there is a growing evidence that omega-3
fatty acids have beneﬁcial effects in chronic inﬂammatory dis-
eases including chronic obstructive pulmonary disease (COPD),
asthma, rheumatoid arthritis, and inﬂammatory bowel disease.2,3
In addition, it is thought that atopic sensitization and allergic out-
comes also can be prevented by ﬁsh intake during pregnancy, in-
fancy, and childhood.4,5 Contemporary changes in diet resulting in a
lower omega-3:omega-6 fatty acid ratio might contribute to exac-
erbation and increased morbidity of asthma and allergic diseases.
Prostaglandins and leukotrienes are arachidonic acid-derived
lipid mediators converted via cyclooxygenase and lipoxygenase,
respectively. Prostaglandin D2 and cysteinyl leukotrienes, produced
mainly by mast cells and eosinophils, function as potent broncho-
constrictors and pro-inﬂammatory molecules in allergic airwayevier B.V. All rights reserved.
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fatty acids such as DHA and EPA function as precursors for bioactive
molecules called resolvins, protectins, and maresins.8,9 Currently,
leukotriene and prostaglandin receptor antagonists are the newest
drugs available for the treatment of asthma, but basic research
ﬁndings now indicate that pro-resolving lipid mediators are
potentially the next therapeutic targets for allergic diseases.
Asthma is a common respiratory disease affecting 300 million
people worldwide.10 Inhaled corticosteroids are an established
treatment, but 5e10% of asthma patients are resistant to this
therapy, leading to difﬁculties in managing the disease.11 Leuko-
triene receptor antagonists are widely used as another ﬁrst-line
therapeutic agent in asthma, suggesting that abnormal lipid
metabolism contributes to disease pathophysiology. Recently,
several reports have indicated that biosynthesis of anti-
inﬂammatory and pro-resolving lipid mediators, lipoxin A4
(LXA4) or protectin D1 (PD1), are dysregulated in severe
asthma,12e21 suggesting that an imbalance between pro- and anti-
inﬂammatory molecules causes the exacerbation of inﬂammation
observed in airways of asthmatic patients.
Epidemiological/clinical studies of omega-3 fatty acids in
asthma and allergic diseases
A large epidemiological study in Greenland showed that intake
of omega-3 fatty acids was inversely associated with asthma
morbidity. Since then, many epidemiological and clinical studies
focusing on omega-3 fatty acid intake or supplements have been
conducted. For example, the concept underlying these studies is
supported by the ﬁnding that the DHA content compared with
arachidonic acid in nasal tissues from patients with asthma was
lower than in healthy subjects,22 which suggests a possible pro-
tective role of DHA in allergic diseases. Thus, it has been of great
interest for some time whether long-chain omega-3 fatty acids or
their natural sources, ﬁsh or ﬁsh oils, have beneﬁcial effects on
asthma or other allergic outcomes.
Many epidemiological studies of maternal ﬁsh intake during
pregnancy have shown beneﬁcial effects on allergic or atopic out-
comes in infants or children of those pregnancies.23e27 In addition,
the majority of reports investigating ﬁsh intake during infancy or
childhood have suggested a protective role in allergic out-
comes.28e36 These allergic or atopic outcomes included incidence
of atopic diseases or symptoms (asthma, wheezing, eczema, and
hay fever), food sensitization, and prevalence of positive skin prick
test (SPT). One study of ﬁsh intake during lactation demonstrated
that higher levels of EPA in breast milk correlated with a lower risk
of atopic dermatitis.37 On the other hand, observational studies in
adults have been inconsistent in showing beneﬁts in asthma of ﬁsh
or ﬁsh oil intake.38e45 However, several reports indicated that
omega-3 fatty acid intake lower asthma incidence, prevalence of
asthma-related symptoms, or exhaled nitric oxide (NO) levels and
improve lung functions in adults.38,40e43 An epidemiological survey
of young adult Americans revealed that high intake of omega-3
fatty acids, especially DHA compared with EPA, prevented asthma
onset.43 These ﬁndings raise the possibility that omega-3 fatty acids
are useful in the prevention of adult-onset asthma. Another study
also demonstrated superiority of DHA compared to other fatty acids
in terms of improved lung function.42 A relationship between low
omega-3 fatty acid intake and increased respiratory symptoms
(chronic bronchitis, wheeze, and asthma) was shown in another
study,40 suggesting beneﬁcial effects of omega-3 fatty acids in the
lung.
Clinical trials using ﬁsh oil supplementation during pregnancy
and lactation revealed that maternal intake of ﬁsh oil resulted in
higher levels of omega-3 fatty acids in the offspring,46e51 alongwith anti-inﬂammatory changes in immunological parameters
(cytokine production, lipid mediator release, and cellular pop-
ulations).51e57 These studies also suggested that ﬁsh oil supple-
mentation reduced the prevalence and severity of atopic dermatitis
and food sensitization in the ﬁrst year of life, and that these
beneﬁcial effects might persist until adolescence, with a reduced
incidence of eczema, hay fever, and asthma.53,58,59 Fish oil sup-
plementation in infants and children increased the concentrations
of those fatty acids in plasma60e64 and blood cells65 and had
modulatory effects on the immune systems of infants65 and chil-
dren.61,66 Clinical intervention with ﬁsh oil supplements in infants/
children from 6 months old to 5 years old showed that there was a
decreased prevalence of wheeze and lower bronchodilator use at 18
months of age,63,67 and reduced allergic sensitization and preva-
lence of cough at 3 years of age, but without effects on asthma
prevalence.64 Two studies examined whether ﬁsh oil supplements
have beneﬁcial effects on asthmatic symptoms and lung function in
patients with asthma in children,61,68 but in only one study did
intervention signiﬁcantly reduce asthma severity and improve lung
functions.68 The data obtained from clinical trials of ﬁsh oil and
omega-3 fatty acid supplements in adult asthma are inconsistent.
However, several studies demonstrated protective effects of
omega-3 fatty acid supplementation in adult asthmatic
patients.69e72 Mickleborough et al., showed that intake of omega-3
fatty acid supplements reduced bronchoconstriction after exercise
accompanied by lower production of leukotrienes from poly-
morphonuclear cells in athletes71 and adult patients with asthma.70
Two other reports demonstrated the beneﬁcial and suppressive
effects of omega-3-rich supplementation on exhaled NO levels
before and after allergen challenge, serum eosinophil counts,
eosinophilic cationic protein levels, and in vitro cysteinyl leuko-
triene release,72 or daytime wheeze, exhaled H2O2 levels, and
morning PEF, respectively.69 Various factors, e.g., types of oils,
doses, duration, and quality or purity of ﬁsh oil or omega-3 fatty
acid supplements were inconsistent among clinical studies. Char-
acteristics of the subjects in these studies were also different (age,
smoking history, country of origin, medication, etc.). There is clearly
much room for improvement in study design and protocols to
obtain more easily interpretable information.
Omega-3 fatty acids or their metabolites in murine asthma
models
To investigate potential beneﬁcial effects of omega-3 fatty acids
in asthma, it is of interest to determine whether administration or
elevated levels of omega-3 fatty acids can suppress eosinophilic
inﬂammation in vivo. Several reports have indicated that omega-3
fatty acids function as protective molecules in murine models of
asthma,73e76 although those regulatory functions were not
observed in other studies.77,78 DHA inhalation during the allergen
challenge phase in mice suppressed airway eosinophilic inﬂam-
mation, and this was accompanied by reduced numbers of in-
ﬂammatory cells in bronchoalveolar lavage ﬂuid (BALF) and
decreased airway hyperresponsiveness, and mucus production.76
Morin et al., developed a new monoglyceride DHA derivative
(CRBM-0244)74 and EPA derivative (EPA-MAG)75 and showed their
preventive effects on airway eosinophilic inﬂammation, airway
hyperresponsiveness and inﬂammatory cytokine production in
OVA-induced asthmatic responses.
Fat-1 is a C. elegans enzyme that converts omega-6 fatty acids
into omega-3 fatty acids. Fat-1 transgenic mice (Fat-1 mice) have
been established and used as an experimental model to determine
if higher ratios of omega-3 fatty acids to omega-6 fatty acids can
contribute to anti-inﬂammatory responses in various conditions. In
experiments using these mice, substantial amounts of omega-3
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murine model of asthma using OVA, the number of inﬂammatory
cells in BALF, mucus production, airway hyperresponsiveness, and
Th2 cytokine concentrations (IL-5, IL-13) were decreased in the fat-
1 transgenic mice. Lipidomic analysis demonstrated that the levels
of pro-resolving lipid mediators, PD1 and resolvin E1 (RvE1), which
are synthesized in lung, were signiﬁcantly increased in inﬂamed
lungs of fat-1 transgenic mice.73
Pro-resolving lipid mediator (Protectins Resolvins Maresins)
Biosynthesis and cell sources of protectins and resolvins
Lipidomic analysis of murine inﬂammatory exudates or acti-
vated cell supernatant identiﬁed speciﬁc pro-resolving lipid me-
diators, including protectins, resolvins, and maresins, synthesized
from omega-3 fatty acids during the resolution phase. These mol-
ecules are generally termed specialized pro-resolving mediatorsFig. 1. Polyunsaturated fatty acid-derived lipid mediators. Arachidonic acid is a metabolic
as pro-inﬂammatory mediators. In contrast, omega-3 fatty acids are converted to bioactive m
properties.(SPM).8,9,79 Protectins and Resolvin D-series lipid mediators are
produced by 15-lipoxygenase in human and 12/15-lipoxygenase in
mouse. These enzymes convert DHA to 17-hydro(peroxy)docosa-
pentaenoic acid (17-HpDHA), a compound that is further metabo-
lized into protectins and resolvin Ds. Resolvin E series are produced
via the acetylated cyclooxygenase-2 or cytochrome P450 pathways.
These enzymes convert EPA to 18-hydroxyeicosapentaenoic acid
(18-HEPE), which is further metabolized into resolvin Es (Fig. 1).
15-lipoxygenase or 12/15-lipoxygenase are expressed in Th2
cytokine-stimulated monocyte or macrophages, retinal epithelial
cells, microglial cells, and airway epithelial cells. In addition, we
demonstrated that human and murine eosinophils highly
expressing 15-lipoxygenase-1 or 12/15-lipoxygenase have the ca-
pacity to produce PD1.21,80 We also identiﬁed 12/15-lipoxygenase-
dependant anti-inﬂammatory lipid mediators, resolvin E3 and 12-
hydroxy-17,18-epoxyeicosatetraenoic acid.81e83
Cyclooxygenase-2 and cytochrome P450 are expressed in neu-
trophils, macrophages, epithelial cells, and other structural cells.precursor to eicosanoids (i.e. prostaglandins and leukotrienes) that have distinct roles
etabolites such as resolvins and protectins with anti-inﬂammatory and pro-resolving
J. Miyata, M. Arita / Allergology International 64 (2015) 27e3430COX-2 is induced by stimulatory signals in various cells types and
can modify inﬂammatory responses thorough its major metabo-
lites, the prostaglandins. Cellecell interactions between cells
expressing different enzymes are also necessary for the biosyn-
thesis of these mediators.84
Receptors and biological functions
The search for receptors speciﬁc to the newly discovered lipid
mediators e protectins, resolvins, and maresins e is now under-
way, and some receptors with high afﬁnity for resolvin D1 (RvD1),
D3, D5 and RvE1 have been identiﬁed. However, the receptor
speciﬁc for PD1 remains unknown, although its existence on neu-
trophils, pigment epithelial cells, and neuronal cells have been
suggested.85,86 Two high afﬁnity receptors for RvD1 and LXA4,
namely ALX (FPR2, FPRL1) and GPR32, were identiﬁed.87 GPR32 is
also responsive to RvD3 and RvD5.88,89 RvE1, an EPA-derived lipid
mediator, binds to ChemR23, a receptor for chemerin, and antag-
onizes BLT1, a receptor for LTB4.90e92 These mediators possess pro-
resolving functions as inhibitors of neutrophil accumulation into
inﬂammatory sites and promoters of apoptotic cell clearance by
macrophages.93 Many types of inﬂammatory cells, including
eosinophil, mast cells, T cells, and dendritic cells, are also directly
regulated by these mediators.
Pharmacological effects in a murine models of asthma
(Table 1)
(A) Protectin D1 (PD1)
In a murine model of asthma using ovoalbumin (OVA), intra-
venous administration of PD1 decreased the number of inﬂam-
matory cells in BALF and inhibited airway hyperresponsiveness and
mucus production, suggesting protective effects on asthmatic re-
sponses in vivo without changes of IL-5 concentration in BALF.94
TLR7 is necessary for the recognition of single stranded RNA of
respiratory viruses. TLR7 agonists had preventive effects on allergic
airway inﬂammation in vivo in mice95e97 and functioned as bron-
chodilators in humans, indicating that they are potential thera-
peutic targets in asthma. Interestingly, TLR7 signaling promotes the
resolution of airway eosinophilic inﬂammation through upregula-
tion of 12/15-lipoxygenase metabolism, and its metabolites such as
PD1 and RvD1 also showed suppressive effects.98
(B) Resolvin D1 (RvD1)
Intravenous administration of RvD1 inhibited airway eosinophil
accumulation andmucus productionwith decreased IL-5 productionTable 1
Pharmacological effects of SPM in murine models of asthma.
SPM Administration Timing Inﬂam
cell (B
Sensitization Challenge Resolution
PD1 I.V. B B EOSY
RvD1 I.V., I.N. B B EOSY
MF[
RvE1 I.P. B B EOSY
RvE1 I.V. B B EOSY
NK[
LXA4 I.V. B EOSY
LXA4
analog
I.V. B EOSY
Abbreviation: SPM, speciﬁc proresolving mediator; I.V., intravenous; I.N., intranasal; EOS,
hyperresponsiveness; ND, no data.in a murine model of asthma. In vitro, RvD1 promoted phagocytosis
by alveolar macrophages, suggesting that RvD1 enhances the clear-
ance of apoptotic inﬂammatory cells in the airway. Administration of
RvD1 during the resolution phase also dampened eosinophilic
inﬂammation.99,100Asmentioned in thePD1 section, RvD1promoted
the resolution of airway eosinophilic inﬂammation and its biosyn-
thesis was induced in part thorough the TLR7 cascade.98
(C) Resolvin E1 (RvE1)
Various reports have demonstrated the protective effects of
RvE1 on airway eosinophilic inﬂammation in vivo.101e104 In an OVA-
inducedmurine asthmatic model, intraperitoneal administration of
RvE1 during the sensitization phase, challenge phase, or both
inhibited the production of OVA-speciﬁc IgE, inﬂammatory cell
accumulation in the airways, airway hyperresponsiveness, mucus
production, and Th2 cytokine (IL-5, IL-13) production.101,102 In
addition, intravenous administration of RvE1 during the resolution
phase also dampened inﬂammatory cell accumulation in the air-
ways, airway hyperresponsiveness, and mucus production. These
effects were mediated by the inhibition of Th17 cytokines (IL-17A
IL-23 IL-6) and the increased production of IFN-g with no differ-
ences in Th2 cytokines (IL-5・IL-13) between vehicle and RvE1
treated groups.104 In this setting, RvE1 directly modulated cytokine
production by dendritic cells and activated natural killer (NK)
cells,103 the main producers of IFN-g and active inducers of eosin-
ophil apoptosis.105 RvE1 binds to ChemR23, also known as the
chemerin receptor. Recently, a newmembrane-anchored chemerin
receptor agonist was discovered and pharmacological assessment
using a murine model of allergic airway inﬂammation revealed its
immunomodulatory functions.106
Biosynthesis in human asthma (Table 2)
(A) Protectin D1(PD1)
The presence of PD1 in the airways of normal human subjects
has been documented in condensates of exhaled breath, with a
decrease in PD1 levels below the detection limit in exhaled breath
condensates of asthmatic patients during exacerbation of the dis-
ease.94 We found decreased productions of PD1 and 15-HETE, a 15-
lipoxygenase metabolite of arachidonic acid, by stimulated pe-
ripheral blood eosinophils from patients with severe asthma, sug-
gesting an impairment in 15-lipoxygenase activity in severe
asthma.21 In contrast, the similar levels of 5-HETE, a 5-lipoxygenase
product of arachidonic acid, were observed in patients with severe
asthma and healthy subjects, indicating a selectively dysregulated
enzymatic activity of 15-lipoxygenase21 (Fig. 2).matory
ALF)
Cytokines, lipid mediators AHR Mucin Reference
LYMY IL-5/ IL-13Y PGD2Y cysLTsY Y Y 94
LYMY IL-4/ IL-5Y IL-10/ IL-13/
IL-17Y IL-23YCCL11/ CCL17/
IFN-g/ LTB4Y LXA4/
Y Y 100
LYMY IL-4Y IL-5Y IL-13Y CCL5Y IgEY Y Y 101,102
LYMY IL-4/ IL-5/ IL-13/ IL-6Y
IL-17Y IL-23Y IL-27Y IFN-g[
LTB4YcysLTs/ LXA4[
Y Y 103,104
LYMY IL-5Y IL-13Y PGE2Y cysLTsY Y ND 107
LYMY IL-4Y IL-5Y IL-13Y IL-10YCCL5/
cysLTsY
Y ND 108
eosinophil; LYM. Lymphocyte; MF, macrophage; NK, natural killer cell; AHR, airway
Table 2
Impaired biosynthesis of SPM in patients with asthma (severe asthma, asthma exacerbation, AERD, and bronchoconstriction).
SPM Disease Clinical sample Cell type Findings Reference
PD1 Severe asthma WB EOS Decreased PD1 synthesis in eosinophils from severe asthmatics 21
Asthma exacerbation EBC Decreased PD1 concentration during asthma exacerbation 94
LXA4 Severe asthma BALF, EBBs, WB NEU, EOS,
MONO, LYM
Decreased LXA4 concentration in BALF and ALXR expressions on
granulocytes in severe asthma
12
BALF Alveolar
MFAlveolar MF
Lower LXA4 generation in alveolar MF from severe asthmatics
compared with non-severe asthmatics
13
EBC The LXA4/LTB4 ratio is decreased in severe asthma 14
EBC Lower LXA4 concentration in severe to moderate asthma than in
intermittent asthma and healthy status
15
WB Lower LXA4 synthesis in severe asthma than in moderate asthma
with higher CysLTs synthesis
16
WB Lower LXA4 generation in severe asthma than in mild asthma 17
WB LEU Decreased 15-LOX expressions in leukocytes and LXA4
concentration in severe asthma than in mild to moderate asthma
18
Sputum Lower LXA4 concentration in severe asthma than in mild asthma
with higher IL-8 concentration
19,20
AERD WB Lower LXA4 and 15-epi LXA4 synthesis in AIA than in ATA 109
Urine Lower 15-epi LXA4 concentration in AIA 110
Asthma exacerbation EBC Lower LXA4 concentration in asthma than in status asthmatics 111
Bronchoconstriction WB Lower LXA4 concentration after exercise in mild asthma 112
Abbreviation: AERD, aspirin-exacerbated respiratory disease; BALF, bronchial alveolar lavage ﬂuid; EBBs, endobronchial lung biopsy; WB, whole blood; EBC, exhaled breath
conensate; NEU, neutrophil; EOS, eosinophil; MONO, monocyte; LYM, Lymphocyte; MF, macrophage; LEU, leukocytes; CysLTs, cysteinyl leukotrine; LOX, lipoxygenase; ATA,
aspirin-tolerant asthma; AIA, aspirin-intolerant asthma.
Fig. 2. Dysregulation of 15-lipoxygenase pathway in eosinophil from patients with severe asthma. There was a surprisingly marked decrease in the biosynthesis of PD1 by
stimulated peripheral blood eosinophils harvested from patients with severe asthma. In contrast, the levels of 5-HETE, a 5-lipoxygenase-dependent metabolite of arachidonic acid,
were similar in patients and healthy subjects, suggesting a selective dysregulation of the 15-lipoxygenase pathway.
J. Miyata, M. Arita / Allergology International 64 (2015) 27e34 31Several reports showed decreased biosynthesis or levels of
LXA4, a potent anti-inﬂammatory lipid mediator with suppressive
effects on allergic airway inﬂammation in vivo107,108 in BALF,12
exhaled breath condensate,14,15 whole blood,16e18 and sputum19,20
of severe asthmatics. Bhavsar et al., demonstrated that the alve-
olar macrophage was one of the speciﬁc cell types with impaired
LXA4 biosynthetic capacity.13 Similar defects in LXA4 synthesis
were observed in aspirin-exacerbated respiratory disease
(AERD),109,110 asthma exacerbation,111 and exercise-induced bron-
choconstriction in asthma.112 Those observations are concordant
with our observation of selective dysregulation of PD1 synthesis in
human eosinophils, and we propose that impaired fatty acid
metabolism may contribute to the pathogenesis of severe asthma.
In addition, these observations suggest that dysregulation of a
negative feedback system via these pro-resolving molecules mightbe the underlying pathophysiology in severe asthma. Omega-3
fatty acid supplements might not provide sufﬁcient anti-
inﬂammatory activity because of impaired enzymatic activities in
asthma patients. The administration of PD1 or LXA4, or of a
molecule that can enhance their synthetic activities, might offer a
promising therapeutic strategy for severe asthma.
Conclusion
Epidemiological and observational studies strongly supported
the efﬁcacy of omega-3 fatty acids in the prevention or ameliora-
tion of asthma and allergic diseases. Molecular mechanisms have
been revealed in part by the identiﬁcation of fatty acid bioactive
metabolites. Downstream metabolites generated via lipoxygenase
and cyclooxygenase, the specialized pro-resolving mediators
J. Miyata, M. Arita / Allergology International 64 (2015) 27e3432(SPM), possess anti-inﬂammatory properties, offering a more pre-
cise understanding of these beneﬁts in inﬂammatory responses.
Lipidomic analyses revealed dysregulated fatty acid metabolism
in patients with allergic diseases, especially severe asthma. The
mechanism of dysregulation in the 15-lipoxygenase pathway and
its relationship to asthma phenotype (atopy, gender, age, inﬂam-
matory cell type, etc.), medication (corticosteroid, leukotriene re-
ceptor antagonist, anti-IgE antibody, etc.), or cytokines/chemokines
remain to be determined. Further studies of omega-3 fatty acid
metabolism and SPM functions might provide therapeutic targets
for the prevention and treatment of asthma and other allergic
diseases.
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